NANOMEDICAMENTS POUR LE TRAITEMENT ... - Collège de France

NANOMEDICAMENTS POUR LE TRAITEMENT DES

MALADIES INFECTIEUSES

P.COUVREURProfesseur au Collège de

FranceChaire d’innovation

Technologique 2009-2010

BetalactaminesHAA-

AminoglycosidesBH+B

B

BH+ Bactéries

quiescentes

En réplication

ClindamycineFluoroquinolones

Clindamycinefluoroquinolones

Active transport

Active transport

+Concentration+Durée de l’exposition-Dégradation-Inactivation? Effet sur l’hôte

PROBLEMATIQUE

TRAFIC INTRACELLULAIRE DES NANOVECTEURSH. Hillaireau and P. Couvreur, CMLS, 2009

Liposome or nanoparticle

Intracellular bacterium

E Endosome

PL Phagolysosome

PL

E

E

NucleusTRAFIC INTRACELLULAIRE

DES NANOVECTEURS VERSUS LES

MICROORGANISMES

! FUSION PROCESSES ARE NEEDED !

INTRACELLULAR INFECTIONS BY BACTERIA

CELL FEATURES

J774 CELL UPTAKE OF GENTAMICINE LIPOSOMES

37°C

4°C

P; Lutwyche et al, Antimicrobial Agents and Chemotherapy, 42, 2511-2520 (1998)

[A] J774 capture of different liposomal formulations [B] J774 capture of gentamicine

Cell membrane is relatively impermeable to gentamicine

DOPE are pH-sensitive formulations DDAC is a + charged formulation

KILLING INTRACELLULAR S.typhimurium BY GENTAMICINE LIPOSOMES

P; Lutwyche et al, Antimicrobial Agents and Chemotherapy, 42, 2511-2520 (1998)

Gentamicine conc.: 150 microgr/ml

DOPE pH sensitive liposomes are the more efficient

P; Lutwyche et al, Antimicrobial Agents and Chemotherapy, 42, 2511-2520 (1998)

KILLING INTRACELLULAR RECOMBINANT HEMOLYSIN S.typhimurium BY GENTAMICINE LIPOSOMES

S. Typhimurium wild type lysosomal localizationS. Typhimurium recombinant hemolysincytoplasmic localization (escape from lysosomes)

DOPE

LYS.

CYT.

pH=5

KILLING INTRACELLULAR L.monocytogenes BY GENTAMICINE LIPOSOMES

P; Lutwyche et al, Antimicrobial Agents and Chemotherapy, 42, 2511-2520 (1998)

L. Monocytogenes resides in cytosol

• Corrected killing values were obtained by subtraction of the mean killing observed for free gentamicin from that for the encapsulated gentamicin and dividing by the nanomoles of lipid taken up per 106 cells

COMPARISON OF INTRACELLULAR KILLING BY GENTAMICINE LIPOSOMES OF S. typhimurium WILD

TYPE and HEMOLYSIN AND L.monocytogenesP. Lutwyche et al, Antimicrobial Agents and Chemotherapy, 42, 2511-2520 (1998)

S. thyphimurium wild type

S. typhimurium hemolysin

L; monocytogenes

• Lipid mixing activities of gentamicin-containing DOPE-N-succinyl-DOPE-PEG (69.5:30:0.5) (open squares), DOPC-N-succinyl-DOPE-PEG (69.5:30:0.5) (closed circles), and DPPC-Chol (55:45) (open triangles) were monitored by a resonance energy transfer fluorescence dequenching assay

(A) Time course of mixing at pH 4.86 (for the DOPC-containing formulation) and 4.87 (for the DOPE- and DPPC-containing formulations).

(B) pH dependence of lipid mixing after 1 min of incubation.

C) pH dependence of lipid mixing after 1 min in serum-free medium containing 20 mM Ca2+.

LIPID MIXING OF GENTAMICINE LOADED LIPOSOMESP; Lutwyche et al, Antimicrobial Agents and Chemotherapy, 42, 2511-2520 (1998)

NBDE and Rhodamine are quenching one another and are incorporated in liposomal formulations. Then, in the presence of unlabelled liposomes, dequenching occurs if fusion between liposomes occurs (due to DOPE)

+

Dequenching of fluorescence

Rho NBDE

• (A) DOPE-containing formulation + Texas red ovalbumin fluorescence showing endocytic pathway (B) DOPE-containing formulation, 5-sulfofluorescein (SFDA) fluorescence

• (C and D) as for panels A and B, respectively, but in the presence of bafilomycin, an inhibitor of lysosomal acidification

• (E) DOPC-containing formulation + Texas red ovalbumin fluorescence; (F) DOPC-containing formulation, 5-SFDA fluorescence

• (G and H) as for panels E and F, respectively, but in the presence of bafilomycin.

INTRACELLULAR CAPTURE OF DIFFERENT LIPOSOMAL FORMULATIONS

P. Lutwyche et al, Antimicrobial Agents and Chemotherapy, 42, 2511-2520 (1998)

J774 capture of DOPE-lip is >>> DOPC-lip but inhibited by bafilomycin which inhibit acidification of endosomes needed for lipid mixing

INFECTIONS BACTERIENNES INTRACELLULAIRES

VOIE INTRAVEINEUSE

RED BLOOD CELL HEMOLYSIS OF FREE AND LIPOSOMAL CLOFAZIMINE

R. T. Mehta, Antimicrobial Agents and Chemotherapy , 40, 1893-1902 (1996)

Clofazimine is an antimycobacterial drug with hemolytic toxicity

Clofazimine is active against mycobacterium and leprae

MORPHOLOGY OF MACROPHAGES TREATED WITH FREE OR LIPOSOMAL CLOFAZIMINE

R. T. Mehta, Antimicrobial Agents and Chemotherapy , 40, 1893-1902 (1996)

2 µg/ml

12 µg/ml

100 µg/ml

Liposome Clofazimine

Free Clofazimine

solvent

IN VIVO TOXICITY OF FREE AND LIPOSOMAL CLOFAZIMINE

Liposomal ClofazimineFreeClofazimine

R. T. Mehta, Antimicrobial Agents and Chemotherapy , 40, 1893-1902 (1996)

MORPHOLOGY AND BACTERIAL COUNTS OF ORGANS OF MICE INFECTED BY IV INJECTION OF VARIOUS LOADS OF

MYCOBACTERIUM AVIUM

Splenomegaly

Lungs liver spleen

R. T. Mehta, Antimicrobial Agents and Chemotherapy , 40, 1893-1902 (1996)

IN VIVO EFFICACY OF FREE AND LIPOSOMAL CLOFAZIMINE ON MICE INFECTED WITH MYCOBACTERIUM AVIUM

R. T. Mehta, Antimicrobial Agents and Chemotherapy , 40, 1893-1902 (1996)

Treatment started day 28 (iv injection) when infection has been established:- Free Clofazimine (F-clof) 5 and 10 mg/Kg- Liposome Clofazimine (L-clof) 5, 10, 25 and 50 mg/Kg

TREATMENT OF MICE INFECTED WITH M. tuberculosisL B Adams et al, Antimicrobial Agents andChemotherapy, 43, 1638-1643 (1999)

left untreated ( ) or treated i.v. every 3 to 4 days over a 2-week period (total, five injections) beginning on day 92 postinfection (established infection) with L-CLF ( , 50 mg/kg; , 5 mg/kg), F-CLF ( , 5 mg/kg), or empty liposomes ( , lipid content equivalent to 50-mg/kg dose).

EFFECT OF CLF LIPOSOMES ON EARLY GRANULOMA FORMATIONL B Adams et al, Antimicrobial Agents andChemotherapy, 43, 1638-1643 (1999)

(A) control mice: intense mononuclear cell infiltration into the lung parenchyma. An early granulomatous response with aggregates of epithelioid macrophages interspersed with lymphocytes

(B) Mice treated with L-CLF: perivascular and peribronchiolar cuffing and more localized granuloma formation without extensive involvement of lung parenchyma.

Scintigraphic images of rats with an unilateral S. aureus infection

0, 1, 6 and 24 h post injection of 99mTc-labeled PEG-liposomes

Laverman P. et al, J Control Rel, 75, 347-355 (2001)

IN VIVO EFFICACY OF ISONIASID AND RIFAMPICIN PEGYLATED LIPOSOMES ON MYCOBACTERIUM TUBERCULOSIS

P. Deol and al, Antimicrobial Agents and Chemotherapy, 41, 1211-1214 (1997)

Untreated controlsFree drugDrug in PEGylated liposomes

ISONIASID RIFAMPICIN

IV administration of 12 mg/KgInsert 12 mg/Kg free drug and 4

mg/Kg in liposomes

INFECTIONS BACTERIENNES INTRACELLULAIRES

VOIE PULMONAIRE

CIPROFLOXACIN SUV LIPOSOMES BY AEROSOL INHALATION AGAINST PULMONARY INFECTION BY Francisella tularensis

P. Wong et al., J Controlled Release, 92, 265-273 (2003)

F. tularensis (Tularemia) involves the RES and leads to bacterial growth in lungs, liver and spleen

Chono et al, J Control. Rel., 127, 50-58 (2008)

CIPROFLOXACIN TARGETING TO ALVEOLAR MACROPHAGES BY PULMONARY ADMINISTRATION OF MANNOSYLATED LIPOSOMES

AM= Alveolar macrophages ELF= Epithelial lining fluid

Ciproflox Conc. (HPLC)[3H] Cholesterolether

INTRACELLULAR INFECTIONS BY PARASITES

LEISHMANIA DONOVANI (Leishmaniasis)PLASMODIUM (Malaria)

Carl R Alving et al, Proc Natl Acad Sci USA, 75, 2959-2963 (1978)

VISCERAL LEISHMANIASIS: SUPERIOR EFFICACY OF LIPOSOME ENCAPSULATED ANTIMONIAL DRUGS

Liposomal meglumine and stibogluconate

Meglumine free

Stibogluconate free

Hamster liver showing lamellar structure of DMPC/Chol/DCP liposome adjascent to intracellular parasite (inj. 35 days after infection)

Treatment 17 days after infection of hamsters by L. Donovani

TREATMENT OF MICE INFECTED WITH L. DONOVANI BY SODIUM ANTIMONY GLUCONATE (SAG) ENCAPSULATED STEARYLAMINE-PC LIPOSOMES

(A and B) Mice were sacrificed on days 1, 15, and 30 posttreatment. Levels of parasite burden in liver (A) and spleen (B) are expressed in Leishman Donovan units.

(C and D) In the second set, efficacy of the combination therapy for treatment of heavy parasite infection was assessed (12 weeks). Liver (C) and spleen (D) parasite loads after 1 month of treatment are shown in Leishman Donovan units.

Swati Pal and al, Antimicrobial Agents and Chemotherapy, 48, 3591-3593 (2004)

! Single dose of(16 mg/Kg) SAG resulted in

complete elimination of parasite !

BINDING OF mAb-LIPOSOMES TO PLASMODIUM BERGHEI INFECTED ERYTHROCYTES

M. Owais et al., Antimicrobial Agents and Chemotherapy, 39, 180-184 (1995)

P. Berghei infected erythrocytes

Uninfected erythrocytes

[A] Non relevant antibody mIg-Lip

[B] relevant antibody mAb D2-Lip binds to both infected and non infectederythrocytes

[C] relevant antibody mAb F10-Lip binds only to infected erythrocytes

Monoclonal antibodies were obtained from mice immunized with membranes of P.berghei infected erythrocytes

TISSUE DISTRIBUTION OF mAb-LIPOSOMES AFTER IV INJECTION TO INFECTED MICE

M. Owais et al., Antimicrobial Agents and Chemotherapy, 39, 180-184 (1995)

Healthy mice

Infected mice

mAb D2-Lip

mAb F10-Lip

mIg-Lip

Plasma RBC Liver

Plasma RBC Liver

IN VIVO EFFICACY OF CHLOROQUINE IMMUNOLIPOSOMES AGAINST CHLOROQUINE-RESISTANT P.berghei INFECTION

TREATMENT(iv 5 mg/ kg days 4

and 6)

6 8 10

Saline 1.57 0.38 4.33 0.90 All dead

Free Chloroquine 1.70 0.34 4.20 1.80 All dead

PAb-lip-Chloroquine 1.36 0.39 3.40 0.75 6.80 1.20

MAbD2-lip-Chloroquine

1.20 0.39 3.23 0.73 4.56 1.39

MAbF10-lip-Chloroquine

1.12 0.20 1.58 0.26 2.58 1.10

% PARASITEMIA ON FOLLOWING DAYS POST-TREATMENT

M. Owais et al., Antimicrobial Agents and Chemotherapy, 39, 180-184 (1995)

Overcoming chloroquine resistance by MabF10-lip may result to reduced efflux of chloroquine from the resistant parasites

SYSTEMIC MYCOSIS

CandidosesAspergilloses

Cryptococcoses

CHEMICAL STRUCTURE OF AMPHOTHERICIN BLuke S.S. Guo, Advanced Drug Delivery Reviews 47,149-163, (2001)

PROPOSED MODEL STRUCTURE OF ABCD

Top: Cartoon molecules of SCS and AMB.

Middle: cross-section view of ABCD shows a bilayer of SCS with AMB interspersed within it.

Bottom: side view of a discoidal complex. AMB forms a shield at the disc edges and is oriented so that the seven hydroxyl groups (black dots) along its side are exposed to the polar aqueous environment.

Luke S.S. Guo, Advanced Drug Delivery Reviews 47,149-163, (200

ABCD or AMPHOCIL is a colloidal complex of Amphothericin B with

Cholesterylsulfate

ELECTRON MICROSCOPY OF ABCD

• (Top) Negative staining • (Middle) Platinum-

shadowing a shadowed polystyrene bead (seen as a white spherical particle) of 109 nm diameter

• (Bottom) Thin-sectioning: parallel layers were revealed, delineated by dark bands.

Luke S.S. Guo, Advanced Drug Delivery Reviews 47,149-163, (2001)

PHARMACOKINETICS AND BIODISTRIBUTION OF CONVENTIONAL AMPHOTHERICIN B (CAB) AND

ABCD IN RATSLuke S.S. Guo, Advanced Drug Delivery Reviews 47,149-163, (2001)

VIRAL DISEASES

i-Pr2NEt, HBTU, HOBt, DMF,

20 °C,48 h

O

OO

A

B

N

N

N

NH

O

HOO

N

N

NH

O

HOO

N

N

NH2

O

O

N

N

N

NH

O

HOO

50%

51%

5'

44

5'

CO2H

O

HO

O

FOH

FH

HH

N

N

NH

O

HO

O

FOH

FH

HH

N

N

NH2

O

1) ClCO2Et, Et3N, THF, -15 °C2) DMF, 20 °C, 3 days

"C27 Squalenic acid"

55%

4-(N)-trisnorsqualenoylgemcitabine

i-Pr2NEt, HBTU, HOBt, DMF,

20 °C,48 h

THE CONCEPTOF

SQUALENIZATION

ddI

ddC

Nanoparticles 100-150 nm

Mais aussi AZT, ARA-C, Thymidine…

ddC-SQ

ddI-SQ

gem

Gem-SQ

Couvreur et al., Nano Letters, 6, 2544-2548 (2006)

Drug loading: almost 50% !

Aoun et al., Advanced Funct Mater, in press, 2008

Squalenoylgemcitabine

O

H H

HO

OH

H

F

O

N

N

O

NH C

F

HO

N

NH

ONO

HH

HHHH

O

ddC-SQ

STRUCTURE OF SQUALENOYLATED ddC

ANTI-HIV ACTIVITY OF ddI-SQUALENE ON HIV INFECTED LYMPHOCYTES

0

0,1

0,2

0,3

0,4

0,5

0,6

0,7

0,8

SensHIV LAI

ddIddI-SQ

05

1015202530354045

SensHIV-1-

LAI

Res HIV-1-144

Res HIV-1-146

ddIddI-SQ

ED50

(mM

)ED

50 (m

M)

1 µM (moyenne)

0

50

100

150

200

250

300

350

2 4 6 24 72 168

Temps (h)

ddA-T

P (

fmol/m

illion

ddIddI-SQ

Intracellular concentration of ddA-PPP

sensitive

resistant

Couvreur et al., Nano Letters, 6, 2544-2548 (2006)

A BIOMIMETIC APPROACH: USING PARASITE TOOLS TO

TARGET SPECIFIC CELLULAR COMPARTMENTS

K. J. Longmuir et al, Pharmaceutical Research? 23, 759-769 (2006)

EFFECTIVE TARGETING OF LIPOSOMES TO HEPATOCYTES BY INCORPORATION OF Plasmodium AMINO SEQUENCE

Control liposomes

Peptide containing liposomesFluorescence in organs

FormulationDierucoylphosphatidylcholine 82%

Dierucoylphosphatidylcholine-PEG5000 10%Dierucoylphosphatidylcholine-PEG-Peptide 4%Dierucoylphosphatidylcholine-Bodipy-TR-X 4%

(red fluorescence)

THE BIOMIMETIC APPROACH:The19-amino acid sequence of circumsporozoite protein (CSP) binds to the highly sulfated heparan sulfate proteoglycans found in the liver located on the basolateral site of the hepatocytes and Disse space

K. J. Longmuir et al, Pharmaceutical Research, 23, 759-769 (2006)

EFFECTIVE TARGETING OF LIPOSOMES TO HEPATOCYTES BY INCORPORATION OF Plasmodium AMINO SEQUENCE

[A] Liver section showing the red fluorescence of Liposomes with liver-targeting peptide plus body-TR-X (red).concentration in hepatocytes (except nucleus) + predominantly labelled regions adjascent to sinusoidal capillaries

[B] Same section under fluorescein optics suitable for green illumination of Body-FL from control liposomes

peptide-liposomes labelled with body-TR-X (red) + control liposomes with Body-FL (green)

EFFECTIVE TARGETING OF LIPOSOMES TO HEPATOCYTES BY INCORPORATION OF Plasmodium AMINO SEQUENCE

K. J. Longmuir et al, Pharmaceutical Research, 23, 759-769 (2006)

Gold labelled peptide-liposomes overlying cytoplasm of an endothelial cell (E), hepatocyte (H) and Kupfer cell (K)Lumen of the capillary (L) and Disse space (D)

Just as Plasmodium, liposomes are located in cell cytoplasm and not into the nucleus

LIPOSOME BINDING TO ENZYME TREATED SLICESK. J. Longmuir et al, Pharmaceutical Research, 23, 759-769 (2006)

Control looks like in vivo treated mice

Chondoitinase treated slices has no influence on liposome binding

Heparinase treated slices eliminated liposomes binding Specificity for heparan sulfate proteoglycans

LES NANOMEDICAMENTS ANTIMICROBIENS: UN CHEVAL DE TROIE POUR LES

MICROORGANISMES A LOCALISATION INTRACELLULAIRE